Wyeth Seeks Silver Lining In Series Of Regulatory Setbacks
Executive Summary
Wyeth believes that offering a lower dose of its serotonin-norepinephrine reuptake inhibitor Pristiq will better position the drug to compete in the major depressive disorder market
You may also be interested in...
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective
Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective
Wyeth’s Hot Flash: Pristiq “Approvable” Delays Vasomotor Claim At Least A Year
Building a stable of next-generation women's health products is not coming easily to Wyeth. The drug maker received an "approvable" letter July 23 for its Effexor XR follow-on Pristiq for treatment of vasomotor symptoms of menopause, including night sweats and hot flashes